A phase 2 trial of Memo Therapeutics’ kidney transplant drug candidate has missed its primary endpoint, adding to the list of ...

Roche’s move came against a backdrop of wider industry retreat from gene therapy, with Pfizer pulling its FDA-approved ...

Bristol Myers Squibb has raided AstraZeneca to find its next chief medical officer (CMO), persuading Cristian Massacesi, M.D.

Adicet Bio is handing out pink slips to 30% of its staffers in tandem with a pipeline restructure that includes discontinuing ...

Australian life sciences venture capital firm Brandon Capital has closed its largest fund yet, raising A$439 million (about ...

Ikena and Inmagene have selected Kristin Yarema, Ph.D., to lead the company upon the anticipated closing of their merger.

Eli Lilly is walking through the Gate, inking a deal worth up to $856 million with a biotech aiming to build out a new ...

Novartis is serving up $60 million to partner with Matchpoint Therapeutics in hopes of getting an oral covalent inhibitor ...

The company’s TYK2 inhibitor GLPG3667 sits on the chopping block as well. Galapagos is “actively exploring partnership ...

Olympus has teamed up with Revival Healthcare Capital to launch a joint venture aimed at bringing robotics to ...

Roche has obtained European approval for a blood test to help rule out Alzheimer’s disease, allowing patients to avoid ...

The orthopedic implant maker Shoulder Innovations is the latest medtech to plan for a nine-figure IPO, as it looks to scale ...